Cytochrome P450 (P450, CYP) 17A1 plays a critical role in steroid metabolism, catalyzing both the 17␣-hydroxylation of pregnenolone and progesterone and the subsequent 17␣,20-lyase reactions to form dehydroepiandrosterone (DHEA) and androstenedione (Andro), respectively, critical for generating glucocorticoids and androgens. Human P450 17A1 reaction rates examined are enhanced by the accessory protein cytochrome b 5 (b 5 ), but the exact role of b 5 in P450 17A1catalyzed reactions is unclear as are several details of these reactions. Here, we examined in detail the processivity of the 17␣-hydroxylation and lyase steps. b 5 did not enhance reaction rates by decreasing the k off rates of any of the steroids. Steroid binding to P450 17A1 was more complex than a simple two-state system. Pre-steady-state experiments indicated lag phases for Andro production from progesterone and for DHEA from pregnenolone, indicating a distributive character of the enzyme. However, we observed processivity in pregnenolone/DHEA pulse-chase experiments. (S)-Orteronel was three times more inhibitory toward the conversion of 17␣hydroxypregnenolone to DHEA than toward the 17␣-hydroxylation of pregnenolone. IC 50 values for (S)-orteronel were identical for blocking DHEA formation from pregnenolone and for 17␣-hydroxylation, suggestive of processivity. Global kinetic modeling helped assign sets of rate constants for individual or groups of reactions, indicating that human P450 17A1 is an inherently distributive enzyme but that some processivity is present, i.e. some of the 17␣-OH pregnenolone formed from pregnenolone did not dissociate from P450 17A1 before conversion to DHEA. Our results also suggest multiple conformations of P450 17A1, as previously proposed on the basis of NMR spectroscopy and X-ray crystallography.
The cytochrome P450 (P450 or CYP) 3 enzymes collectively have the most diverse set of substrates, at least among oxidoreductases (1) . In particular, P450s are very important catalysts in the metabolism of steroids (human P450s 1B1, 7A1, 7B1, 8B1, 11A1, 11B1, 11B2, 17A1, 19A1, 21A2, 24A1, 27A1, 39A1, 46A1, and 51A1, plus some others involved in catabolism) and vitamins (human P450s 2R1, 24A1, 26A1, 26B1, 26C1, 27A1, 27B1, and 27C1) (2, 3) . The steroidogenic P450s are particularly important, and homozygous or dual heterozygous deficiencies are often debilitating (2, 4) . P450 enzymes also have major roles in the metabolism of exogenous (xenobiotic) chemicals, including drugs and carcinogens (3) , and some P450s oxidize both endogenous and xenobiotic substrates (5) .
One of the steroidogenic P450s, P450 17A1, has a critical role in the production of androgens and also glucocorticoids (2) . At least 50 variants with P450 17A1 insufficiency have been identified clinically (4, 6) . The enzyme catalyzes the two-step oxidation of progesterone to 17␣-OH progesterone to androstenedione (Andro) and also the oxidation of pregnenolone to 17␣-OH pregnenolone to dehydroepiandrosterone (DHEA) (Fig. 1 ). The second reaction in each series (Fig. 1A) is termed a "lyase" (or "desmolase") reaction, in that cleavage of the 17,20 C-C bond occurs. Although these were first considered to be separate enzymatic activities, they are now known to be catalyzed by a single protein, P450 17A1 (7) (8) (9) . The presence of another hemoprotein, cytochrome b 5 (b 5 ), has been shown to greatly stimulate the lyase activity (10 -13) , at least in some species. The process is complicated by accompanying minor reactions (Fig. 1B) . The minor products have all been identified in vitro (14 -16) , and 16␣-OH progesterone has been measured in human serum (17) .
A role for b 5 in enhancing P450 catalytic activity was first shown in liver microsomes in 1971 (18, 19) . In 1982, b 5 was shown to stimulate the 17␣-OH progesterone lyase activity of purified porcine testicular P450 17A1 3-4-fold (10, 20) . Kominami et al. (21) also showed stimulation of guinea pig P450 17A1 by bovine b 5 , both the 17␣-hydroxylation of progesterone and, to a fractionally larger extent, the 17␣-OH progesterone lyase reaction. However, b 5 was inhibitory at a b 5 /P450 17A1 ratio of Ͼ0.5 (21) . In 1995, Katagiri et al. (11) reported that human b 5 (added in a concentration equimolar to P450) stimulated several catalytic activities of human P450 17A1. Progesterone 17␣-hydroxylation was not stimulated by b 5 , but pregnenolone 17␣-hydroxylation was enhanced 2.5-fold; lyase activities toward both 17␣-OH progesterone and 17␣-OH pregnenolone were enhanced ϳ10-fold by b 5 (11) . No qualitative difference was observed in the binding of 17␣-OH preg-nenolone to P450 17A1. In the same year (1995), Lee-Robichaud et al. (12) also demonstrated stimulation of both porcine and human P450 17A1 activities by porcine b 5 , although the results differed from those of Waterman and coworkers (11) . The catalytic efficiency of 17␣-hydroxylation was increased 2-fold for pregnenolone but not for progesterone, as in the report of Waterman and co-workers (11 (14 -16) .
Human P450 17A1 kinetics
lyase activity with either 17␣-OH progesterone or 17␣-OH pregnenolone (as substrate) could be detected in the absence of b 5 , but activities were seen in the presence of a 5-fold molar excess of b 5 Ͼ P450 17A1 (12) .
There are several enigmas about P450 17A1. One is the exact role of b 5 , which NMR studies indicate occupies the same site as and competes with the obligate electron donor NADPH-P450 reductase (13, 22) . b 5 does not appear to transfer electrons to P450 at any point in the catalytic cycle (23, 24) . Another controversy is whether a ferric peroxide (FeO 2 Ϫ ) or compound I (perferryl oxygen; FeO 3ϩ ) species is involved in the lyase reaction (15, 16, (25) (26) (27) .
One of the issues regarding the two-step, net four-electron oxidation (Fig. 1A) is the processivity of the overall reaction. In a processive reaction, the 17␣-OH steroid product remains bound to the enzyme for the succeeding lyase reaction, but in a distributive reaction, the 17␣-OH product dissociates and then re-binds for the lyase reaction ( Fig. 1A) . A variety of reports on the topic of processivity have appeared, with varying conclusions. On the basis of work in human embryonic kidney (HEK-293) cells, Soucy and Luu-The (28) concluded that this is a distributive sequence of reactions. However, studies with rat, guinea pig, and bovine P450 17A1 enzymes led to conclusions that the two steps are processive (29 -33) . These studies involved a number of approaches and designs, but none included b 5 , which had already been shown to stimulate the lyase reaction (10, 11) . Our own work with zebrafish P450 17A1 and b 5 indicated that the reactions were distributive when progesterone was the substrate and more processive when pregnenolone was the substrate, although only a relatively weak effect of zebrafish or human b 5 is seen in that system (34) .
The matter of processivity is important for several reasons. One is that 17␣-OH progesterone and 17␣-OH pregnenolone (formed following 2-electron reduction of 17␣-OH progesterone) serve as precursors to glucocorticoids (2, 3) . Another issue is that prostate cancer is androgen-stimulated (35) , and P450 17A1 is a major drug target for therapy (6, 36 -39) . A goal is the selective inhibition of the androgen-producing lyase reaction, preserving the ability to generate 17␣-OH steroids as precursors for biosynthesis of glucocorticosteroids and avoiding adverse effects caused by insufficient glucocorticoid and excess mineralocorticoid production. Some selectivity for lyase Ͼ 17␣hydroxylation activity has been reported for abiraterone (36) , orteronel (Takeda TAK-700) (40) , the secosteroid (S)-seviteronel (VT-464) (41) , and two other non-steroidal pyridine derivatives (36) . X-ray crystal structures of human P450 bound to abiraterone (6) and to both enantiomers of orteronel (42) have been published by Scott and co-workers (42) . A completely processive reaction should not have differential sensitivities to a single inhibitor. Even in a dissociative mechanism, the question arises as to how a drug can occupy a single site on the enzyme and have different K i values for two reactions (42, 43) .
For the above reasons, we examined the kinetics of binding of human P450 17A1 to its primary physiological substrates and products and also an enantiomer of orteronel. We also utilized pre-steady-state reaction kinetics and global data analysis to develop a model of the human P450 17A1 reactions.
Results

Steady-state reaction kinetics
These studies began with steady-state reaction kinetics, which included an analysis of the effect of b 5 (Fig. 2 and Table 1 ). Some of the lack of ideal curve fitting may be due to the formation of additional products ( Fig. 1B) (15, 16) , which were not included here for the sake of simplification. The efficient conversion of 17␣-OH pregnenolone to DHEA confounds the results for formation of 17␣-OH pregnenolone from pregnenolone ( Fig. 2A ), but the lyase reaction (using 17␣-OH pregnenolone as the starting substrate ( Fig. 2B) ) was more straightforward. The decrease in apparent rates of DHEA formation in the presence of b 5 (Fig. 2B ) may be the result of facile 16-hydroxylation of DHEA (16) . Our k cat and K m values are similar to those of Lee-Robichaud et al. (12) , and the k cat values are as high or higher than reported for any human P450 17A1 preparations by others (11, 44 -48) .
b 5 stimulated all of the reactions examined ( Fig. 2 ). Very little DHEA was formed from pregnenolone or 17␣-OH pregnenolone in the absence of b 5 (Fig. 2 , A and B) nor was very much Andro formed from progesterone or 17␣-OH progesterone (Fig. 2 , C and D). 16␣-Hydroxylation of progesterone was also enhanced by b 5 (Fig. 2C ). The major effects of b 5 were on k cat values ( Table 1) .
Binding of substrates and products to P450 17A1
Initial experiments were done with low concentrations of P450 17A1 in a 10-cm cell (34) because of the low K d values we estimated in preliminary assays, which were done using the "type I" Soret spectral shifts (increase in absorbance at 390 nm and decrease near 420 nm (49) ). Because of issues we found regarding the instability of P450 17A1 during the protracted measurements, we collected data (following stopped-flow mixing) 7 s after additions and used these results, utilizing a quadratic equation for fitting. The apparent K d values for pregnenolone, progesterone, 17␣-OH progesterone, and 17␣-OH pregnenolone were all sub-micromolar ( Fig. 3 ). The K d value for DHEA was 1.7 M and that for Andro was ϳ19 M, although the K d fitting for the latter product was not very accurate.
Measurement of k off rates of substrates and products of P450 17A1
One of the possible roles of b 5 in the enhancement of the lyase reactions could be the decreased dissociation of 17␣-OH steroids ( Fig. 1A ). If this were the case, the k off rates would be expected to be lower in the presence of b 5 .
Because of the different Soret spectra observed with various ligands (Figs. 4 and 5) and the interaction of the imidazole group of orteronel with the heme iron (34), we were able to use this compound as a trap (the estimated K d for (S)-orteronel is 40 nM (42), which we confirmed (data not presented)). With 10 M (S)-orteronel, the apparent on-rate was 6.1 s Ϫ1 (Fig.  4 ). Mixing of equimolar concentrations (2 M) of P450 17A1 and each steroid with 10 M (S)-orteronel provided a means of estimating k off values, in that these were 1-2 orders of magnitude slower. Spectral data and analysis for 17␣-OH pregnenolone (as an example) are presented in Fig. 5 (k off 0.4 s Ϫ1 in that example, 0.32 Ϯ 0.02 s Ϫ1 for an average of more experiments in Table 2 ).
The trapping method was used to measure k off rates for all steroid substrates and products ( Table 2 ). In no case did b 5 substantially affect k off values.
Time courses of individual P450 17A1 reactions
P450 17A1 reactions were initiated with equal concentrations (2 M) of P450 17A1 and each substrate ( Fig. 6 ).
(These experiments are often termed "single-turnover" assays, although the term is not strictly correct in that substrate binding and release are occurring on similar time scales as substrate turnover.) In these assays, we also measured minor products to better account for reaction stoichiometry. Several apparent first-order rates of substrate disappearance were calculated and are presented in Table 3 (see also supplemental Fig. S1 ). Table 1 for calculated values. A, pregnenolone (preg); B, 17␣-OH pregnenolone; C, progesterone (prog); D, 17␣-OH progesterone. The rate was too low to accurately measure the steady-state kinetic parameters (see Fig. 6A ). All reactions were stimulated by the presence of b 5 , with the exception of the rate of progesterone disappearance (Fig. 6 , E and F). As expected, all secondary products showed lags in formation, including the lyase products DHEA and Andro (Fig. 6 , B and F).
Pulse-chase assays with pregnenolone oxidation to DHEA
The lag phases for formation of lyase products (DHEA from pregnenolone and Andro from progesterone) ( Fig. 6 , B and F) are indicative of distributive mechanisms, in that a completely processive mechanism should proceed without a lag. The lag phase was shorter in the case of pregnenolone (no DHEA appearing until 2 s, Fig. 2F ) than progesterone (no Andro appearing until 5 s, Fig. 2B ), and we examined this reaction further utilizing pulse-chase assays ( Fig. 7) .
Reactions were initiated with [ 3 H]pregnenolone. In steadystate assays ( Fig. 7A ), unlabeled 17␣-OH pregnenolone was added 60 s after the reaction was initiated, and the reaction proceeded for another 10 min. Even with adding a concentration of unlabeled 17␣-OH pregnenolone as high as 75 M, only about one-half of the [ 3 H]DHEA formed from [ 3 H]pregnenolone could be blocked.
In pre-steady-state reactions, patterned after the experiment in Fig. 6B , a chase of 80 M unlabeled 17␣-OH pregnenolone was added to the reaction at varying times after the reaction started, and the reaction proceeded for another 5 s ( Fig. 7B ). Even when the chase (unlabeled) 17␣-OH pregnenolone was added as early as 50 ms, the production of [ 3 H]DHEA was only blocked by ϳ 1 ⁄ 3. Collectively these results indicate a partially processive mechanism ( Fig. 7) , which is more pronounced with pregnenolone oxidation to DHEA than for progesterone conversion to Andro (Fig. 6 , B and F).
Inhibition of P450 17A1 reactions by orteronel enantiomers
One of the goals in prostate cancer chemotherapy is attenuation of androgen production by selective inhibition of the lyase reaction without disturbing the formation of 17␣-OH products, which are necessary for the formation of other steroids (2) .
The (S) enantiomer of orteronel (supplemental Fig. S2 ) was more inhibitory than the (R) enantiomer in all reactions ( Fig. 8 ).
In the case of progesterone, both enantiomers were slightly more inhibitory for the lyase reaction than 17␣-hydroxylation (Table 4 ). In the reactions with pregnenolone, the IC 50 value for the lyase reaction was ϳ 1 ⁄ 3 that for 17␣-hydroxylation. When the overall conversion of pregnenolone to DHEA was analyzed ( Fig. 8B ), the IC 50 values (for both enantiomers) were similar to those measured for 17␣-hydroxylation ( Fig. 8A ).
Development of kinetic models
For initial model development, we used the measured k off and K d values to estimate apparent k on rates ( Table 5 ). The k on rates were not affected by the presence of b 5 (supplemental Fig.  S3 ). We also measured some k on rates directly, but these are complex and will be considered separately (see below, Fig. 11 ). Only the systems containing b 5 were considered. The oxidation step rates are those measured in the single-turnover reactions presented in Fig. 6 , B, D, F, and G.
Using the simplified model and values listed in Fig. 9 , it was possible to fit the data using KinTek Explorer software ( Fig. 4C was repeated except that the P450 17A1 in the starting system was bound in a 1:1 molar complex with 17␣-OH pregnenolone, and the scan was extended to 10 s using the averaging mode (62 scans/s). A, series of spectra collected at 1-ms intervals over a total period of 1.0 s (only a subset is shown). B, calculated beginning and ending spectra after SVD analysis using a two-species model in the OLIS GlobalWorksா software. C, SVD analysis of data for disappearance of starting species and appearance of final species, along with OLIS EV (Eigenvector) absorbance and OLIS normalized experimental data. Under these conditions (4 M P450 17A1 (E) and 4 M 17␣-OH pregnenolone (S) and using the K d value of 0.52 M ( Fig. 3 
). The calculated k off rate was 0.4 s Ϫ1 (D, with the residuals shown in E). This is a single experiment; for the entire set of averaged experiments see Table 2 . 10) for single-turnover ( Fig. 10, A and B) , steady-state ( Fig. 10 , C and D), and binding reactions ( Fig. 10 , E-G). As mentioned in the presentation of Fig. 2 (see above) , some of the discrepancy may be due to not including all secondary products (14 -16) . We also considered the binding of pregnenolone, 17␣-OH pregnenolone, and DHEA in detail, using global analysis of the actual kinetic binding curves (Fig. 11 ). The k off values used were approximately those measured in the trapping experiments (Table 2) . However, the k on rates are slower than estimated from consideration of k off and K d values ( Table 5 ). In addition, the estimated k on values are all Ͻ10 6 M Ϫ1 s Ϫ1 and therefore probably not diffusion-limited (50) .
An alternative binding scheme is proposed, one in which there exist multiple interconverting conformations of P450 17A1 in the absence of ligands. Independent evidence for the existence of multiple conformations comes from the NMR X-ray crystallography and spectroscopy work of Scott and coworkers (22, 42, 44) . Using a model in which both the ligandfree and ligand-bound forms of the enzyme have multiple, inter-convertible conformations, we were able to fit the raw data files for binding of pregnenolone, 17␣-OH pregnenolone, and DHEA to P450 17A1 ( Fig. 12 ).
Discussion
P450 17A1 plays a critical role as the immediate enzyme involved in steroid metabolism following transformation of cholesterol to pregnenolone by another P450, P450 11A1 (2). P450 17A1 deficiency is a major endocrinological issue (3, 4) , but the same enzyme is also a current target in the treatment of prostate cancer (39) . In this study, we investigated several kinetic aspects of how this enzyme works in the catalysis of two successive reactions (Fig. 1A) . We demonstrate that this is an inherently distributive process, in regard to the two successive reactions, with some of the 17␣-OH steroid products dissociating from the enzyme. However, there is some processivity, particularly in the case of pregnenolone, i.e. part of the 17␣-OH steroid pool does not dissociate but remains bound to the enzyme for the second oxidation step. Accordingly, some of the product DHEA is derived from 17␣-OH pregnenolone that has not dissociated from the enzyme (Fig. 7 ). This is, to our knowledge, the first detailed study to consider the processivity of isolated human P450 17A1 and, with the exception of our zebrafish P450 17A work (34) , the first of any with P450 17A1 to consider the role of b 5 in a processivity study, which is critical (Figs. 2 and 6). The fish enzyme is only modestly stimulated by fish or human b 5 (34) . We conclude that b 5 stimulates both the human P450 17A1 17␣-(and 16␣-) hydroxylation and lyase reactions, plus diene formation ( Fig. 6B ). b 5 did not affect the affinity of P450 17A1 for 17␣-OH steroids ( Fig. 3 and Table 2 ). We believe that multiple conformations of P450 17A1 ( Fig. 13 ) are necessary to explain several of the kinetic results, in support of NMR spectroscopic (22) and X-ray crystallographic evidence (42, 44) for the existence of multiple conformations of the protein.
One previous study concluded that human P450 was a processive enzyme, but this work was only done at a cellular level (HEK-293 cells) (28) . Others concluded that the rat (31) and guinea pig (29) enzymes are processive with the substrate progesterone, based on microsomal studies. Another rat microsomal study (30) with progesterone was unclear regarding conclusions about processivity but can be interpreted in the context of a partially processive mechanism. Tagashira et al. (32) concluded that the guinea pig enzyme was processive with the substrate progesterone, and Yamazaki et al. (33) concluded that the bovine enzyme was "20% processive"; all of these studies (except those using microsomes) were done in the absence of b 5 .
It is clear that any results obtained in the absence of b 5 are problematic ( Fig. 2 and Table 1 ). Lee-Robichaud et al. (12) reported no detectable lyase activity with either 17␣-OH pregnenolone or 17␣-OH progesterone in the absence of b 5 , but both we (Figs. 2 and 6) and others (11, 47) did observe low activity with human P450 17A1. b 5 has been proposed to play a critical role in the balance of steroid metabolism, particularly in the production of androgens (11, 12) . One issue is that the role of b 5 in lyase reactions catalyzed by P450 171 varies among species. With zebrafish P450 17A1, the stimulations by (zebrafish) b 5 were only ϳ2-fold (34) . Mice in which b 5 was globally deleted were still viable and reproduced, even though the formation of androgens from progesterone and 17␣-OH progesterone in testis microsomes was severely attenuated, and the (in vivo) intratesticular levels of testosterone were reduced by one-half (51) . In vitro (murine) microsomal 17␣-hydroxylation of progesterone was also reduced ϳ 1 ⁄ 2. Again, there is species variability, and the application to humans is not direct.
In humans, some clinical endocrine disorders involving low levels of androgens have been linked to defective variants of b 5 (52, 53) . In the two cases cited (52, 53) , the (in vivo) levels of 17␣-OH steroids were not compromised. P450 17A1 is primarily an adrenal enzyme, and one question is what the relative levels of b 5 and P450s are there. Some information is available, but the situation is complex in that there are four zones in the adrenal gland: glomerulosa, fasciculate, reticularis, and medulla. To our knowledge, the levels of the relevant enzymes have not been measured in human adrenal tissue. Hamamoto et al. (54) quantitated several enzymes in bovine adrenals using immunochemical methods. P450 17A1 was not measured but another microsomal P450 (21A2), and two mitochondrial P450s (11A1 and 11B1) were. The levels of b 5 were lower than any of the three P450s in all four zones (54) . This situation contrasts with liver, where the microsomal concentrations of (total) P450 and b 5 are similar (55) .
In modeling our results, we focused on grouping several individual steps together, to simplify the system. Our work indicates that substrate binding is more complex than a one-step/ two-state system (Fig. 12 ), but we modeled the system accordingly to satisfy several data sets ( Figs. 9 and 10) . In a similar way, we know that each oxidation sequence (either 17␣hydroxylation or the lyase step) done by P450 17A1 probably involves at least nine distinct steps (56, 57) . We have modeled each of these sets with a single rate or rate constant (Figs. 9 and 11), without trying to discern rate-limiting steps (there is evidence that C-H bond breaking is at least partially rate-limiting in the 17␣-hydroxylation step (14)).
b 5 showed stimulation of all of the P450 17A1 reactions (Fig.  2) . In some previous work, the conclusion was reached that b 5 selectively enhanced the lyase reaction, possibly by stabilizing the ferric peroxide (FeO 2 Ϫ ) form of the enzyme proposed to be selectively involved in the lyase reaction (12, 58) . Our findings that multiple reactions are stimulated by b 5 argue against this conclusion ( Fig. 2 and Table 1 ). Previous evidence that electron transfer to P450 or its oxygenated complex by b 5 is not involved in the stimulation of P450 17A1 catalytic activity (23, 24) is complemented by our more recent findings that P450 17A1 activity supported by the oxygen surrogate iodosylbenzene, in the absence of NADPH-P450 reductase in the system, is also augmented by b 5 (16) .
The stimulatory effects of b 5 ( Table 1 and Fig. 2 ) are clearly not related to differential effects on binding of intermediate products ( Table 2 ). The effects of b 5 on the lyase reactions with both pregnenolone and progesterone were seen in single-turnover experiments (Fig. 6, C, D, G, and H) . What is less clear is why the effect of b 5 on 17␣-hydroxylation in the steady-state kinetic assays ( Fig. 2 and Table 1 ) is much greater than seen in the single-turnover studies (Fig. 6 ). Recently, Peng et al. (47) provided evidence for improvement of electron coupling of P450 17A1 by b 5 , but presumably the same factors would influ-ence abortive oxygen formed in the steady-state and under presteady-state conditions. We do not have a clear definition of exactly what the k cat or K m parameters mean in this complex system, although the stimulation of both 17␣-hydroxylation reactions is quite clear (Fig. 2, A and C) . b 5 is still an enigma in terms of its role in the P450 17A1 system. As already pointed out, there is considerable evidence against a role for electron transfer, i.e. catalytic activity in assays with the heme deleted from b 5 (23) or replaced by manganesesubstituted heme (24) and with the oxygen surrogate iodosylbenzene (16) . A recent publication by Duggal et al. (48) argues for electron transfer from b 5 based on negative results of experiments with Mn 2ϩ -substituted b 5 , in contrast to others (24) . However, the rate of lyase activity with the control b 5 was only ϳ4% of that measured here ( Table 1 and Fig. 2 ) or elsewhere (16 and also see also other rates in Refs. 11, 12, 47) , and a control b 5 experiment with reconstituted iron-substituted heme was not included. The weight of evidence is that b 5 induces conformational changes in P450 17A1 (and probably several other P450s in which it plays a non-redox role (59) in facilitating product formation (13)), possibly through more productive coupling (47) . Exactly how this occurs is unclear. There is NMR evidence that b 5 occupies the same site of P450 17A1 that NADPH-P450 reductase does (22) . An enigma is that this evidence suggests that the P450 17A1-iron oxygen complex, whatever it may be, receives all of its electrons and is in an activated state before the reductase leaves and is replaced by b 5 , which induces a more favorable conformation for catalysis. This process must happen rapidly, occurring in every reaction cycle. Assuming the above conclusion that b 5 and NADPH-P450 reductase compete for the same P450 17A1 site and cannot be bound simultaneously (22) , it is possible that b 5 could bind earlier, but it would have to be released for NADPH-P450 reductase to rebind (to the Fe 2ϩ -O 2 complex) for electron delivery, and then rebind. We previously reported that b 5 could stimulate the lyase activity of P450 17A1 supported by the oxygen surrogate iodosylbenzene (16 A role for multiple P450 17A1 conformations, indicated by NMR spectroscopy (13) and X-ray crystallography (42, 44) , is supported by some of our own results. As indicated, we were unable to fit the substrate-binding data with only a simple twostate system (Fig. 12 ). We propose that not only the ground state form of P450 17A1 but also the substrate-bound form (13, 42, 44) and probably several of the electronic intermediates in the reaction pathway have multiple conformers (Fig. 13) . Such a diagram is consistent with current general thoughts about enzyme mechanisms (60) and is probably operative here (Fig.  13 ). Attempts to expand our kinetic analysis to include extra conformations with KinTek Explorer were unsuccessful due . 9) . A and B are from Fig. 5 , G and H, respectively (single-turnover results). C and D are steady-state kinetic results from Fig. 2, A and B, respectively. A, single-turnover kinetics beginning with pregnenolone (preg). B, single-turnover kinetics beginning with 17␣-OH pregnenolone. C, steady-state kinetics for conversion of pregnenolone to 17␣-OH pregnenolone and DHEA. D, steady-state kinetics of 17␣-OH progesterone oxidation to DHEA. E, steady-state binding of pregnenolone to (ferric) P450 17A1. F, steady-state binding of 17␣-OH pregnenolone to (ferric) P450 17A1. G, steady-state binding of DHEA to (ferric) P450 17A1.
to the complexity of the system, and even if more rate constants could be attached to the system (in Fig. 13 ), we do not have enough data constraints to judge the validity of any modeling that might fit. Therefore, our kinetic conclusions about processivity rely on models in which reaction steps are grouped together ( Figs. 9 and 11 ). The nature of multiple conformations proposed in the scheme in Fig. 13 is unknown. These could be only structural conformers. However, these could also be b 5 -bound and non-b 5 -bound forms (13, 22) , reductase-and non-reductase-bound forms, FeO 2 Ϫ and FeO 3ϩ forms poised to do different reactions (a possibility we have not ruled out (16) ), or forms that preferentially bind orteronel instead of the substrate and product. With an enzyme in which there appears to be only one ligand-binding site, multiple conformations (Fig. 13 ) are required to explain prefer-ential inhibition of individual reactions by any drug. Alternatively, a second enzyme site can exist and might be involved (42) .
A potential issue related to the processivity of P450 17A1 is application to discovery and development of drugs (for prostate cancer) that would only inhibit the lyase reaction, to avoid side effects. A number of reports of selectivity for the lyase reaction Ͼ17␣-hydroxylation have appeared (40 -42, 61, 62) . However, repeated assays with purified P450 17A1/reductase/b 5 systems have yielded less selectivity, and some of the reports of high selectivity have not been confirmed (36, 42) . Our own results with orteronel show IC 50 values (Table 4) Figure 12 . Analysis of P450 17A1 steroid binding kinetics. P450 17A1 (2 M) was mixed with increasing concentrations of pregnenolone, 17␣-OH pregnenolone, or DHEA as described in general under "Experimental procedures" (see Fig. 3 for concentrations, corresponding to the data points there; note, b 5 was not present discrepancies among IC 50 values are attributed to the use of different substrate concentrations, which necessarily affect IC 50 estimates. Some reported selectivity comparisons are not directly related to processivity, in that 17␣-hydroxylation of progesterone has been compared with lyase activity toward 17␣-OH pregnenolone (36) . In some cases, more selectivity has been reported in cell cultures, based only on measurement of endogenous steroids (36, 40, 62) , although the reasons are not clear. Two findings of the recent Petrunak et al. report (42) are particularly important: (i) the two different protein conformations for binding the (R) and (S) enantiomers of orteronel, and (ii) extra binding space near the F/G helix region only in the case of the (S)-orteronel-P450 17A1 complex. The finding of multiple (or at least two) conformations of ligand-bound P450 17A1 is consistent with the complexity of some of our kinetic data (Fig. 12) . Another point is that if there is a second peripheral ligand-binding site in P450 17A1, then it may be possible to have an induced fit component (63) instead of, or in addition to, a conformational selection model ( Fig. 13 ) for P450 17A1. In principle, the second site of ligand binding could possibly be involved in generating reaction-specific inhibition with drugs targeting P450 17A1.
An alternative consideration for achieving reaction-specific inhibition of P450 17A1 is targeting residues that bind b 5 (needed for efficient 17␣-OH pregnenolone lyase activity) ( Fig.  2B and Table 1 ). An issue here is that one would need to identify (b 5 binding) sites that are not needed to bind NADPH-P450 reductase (22) . One approach would be developing drugs to bind residues (e.g. Glu-305, Arg-347, Arg-358, and Arg-449) where natural mutations attenuate lyase activity but not 17␣hydroxylation activity (6, 64) . Arg-347, Arg-358, and Arg-449 were identified as being involved in the interaction of P450 17A1 with b 5 using NMR spectroscopy (22) , and Glu-305 is located in the canonical active site (6) .
In conclusion, we have analyzed several kinetic aspects of catalysis by human P450 17A1, particularly the coupling of the two major steps, 17␣-hydroxylation and the lyase step, with both the substrates progesterone and pregnenolone. b 5 has an ancillary role in several reactions, and some possible roles were ruled out (e.g. enhancing binding of 17␣-OH steroids). The individual sequential reactions are inherently distributive but more processive in the case of pregnenolone than with progesterone (e.g. Fig. 6, B and F, lags) . There is some processivity, especially with pregnenolone, as demonstrated by the pulsechase experiments (Fig. 7 ). Our kinetic model has 17␣-OH pregnenolone undergo a 1:6 partitioning between proceeding to the lyase reaction and dissociation from P450 17A1 ( Figs. 9  and 11 ). In addition to the pulse-chase data, another point of evidence in favor of some processivity of the 17␣-hydroxylation and lyase reactions is the orteronel inhibition results with pregnenolone (Table 3 ). With both enantiomers of orteronel, the lyase reaction was ϳ3-fold more sensitive to orteronel, confirming the results reported by Hara et al. (40) and Petrunak et al. (42) with (S)-orteronel. When DHEA production was measured from pregnenolone, the IC 50 value was similar to the value for the 17␣-hydroxylation reaction, not the lyase reaction (measured beginning with 17␣-OH pregnenolone) ( Table 3) .
This result is consistent with the view that a part of the P450 17A1 proceeds through the reaction without its 17␣-OH pregnenolone being available for exchange (to allow orteronel to enter the active site). In considering the hypothetical scheme presented in Fig. 13 , it is conceivable that one or more conformational form(s) of the enzyme might be in a "processive" mode, whereas others are in a "distributive" mode, and the composite would be the results we observe here. The results have relevance for the development of prostate cancer treatment drugs that selectively inhibit the individual reactions.
Experimental procedures
Reagents
Most of the steroids were obtained from either Sigma or Steraloids (Wilton, NH). DHEA was purchased from Waterstonetech (Carmel, IN). Radiolabeled 17␣-OH pregnenolone was prepared by enzyme-mediated conversion of [7-3 H]pregnenolone (65), with modification. 17␣-OH-[7-3 H]pregnenolone was obtained from a 30-s incubation with the enzyme system described below, devoid of b 5 . The radiolabeled steroid was purified by the chromatographic method used for 3 H-17␣-OH pregnenolone assays, and fractions were collected (with the ␤-RAM system only used to locate the t R of the product, disconnected for the preparative mode). The steroid was extracted from the mobile phase with CH 2 Cl 2 , the organic (lower) layer was transferred to a new vessel, and the solvent was evaporated under a nitrogen stream. The dried extract was dissolved in C 2 H 5 OH, and coelution with commercial 17␣-OH pregnenolone was used to further validate the identity of the radiolabeled compound.
Purification of (R)-orteronel
A racemic orteronel mixture was purchased from ApexBio (Houston, TX) (catalogue number A4326), and the compound was dissolved in CH 3 OH for purification of the enantiomers. The (S) and (R) enantiomers were resolved on a Chiralcel OJ-RH column (4.6 ϫ 150 mm) with an isocratic 63.5% CH 3 OH, 36.5% H 2 O mobile phase (v/v), with baseline resolution. The two enantiomeric fractions with absorbance peaks at 238 nm were collected (supplemental Fig. S2 ). The (S) and (R) fractions were identified using a standard (S)-orteronel sample, which eluted first. (R)-Orteronel was extracted from the aqueous solution with CH 2 Cl 2 and the solvent was evaporated in vacuo. The dried solid was stored at Ϫ20°C until further use. The two enantiomers had identical UV, NMR, and mass spectra, except for a slight difference in the chemical shifts attributed to the solvent (CD 3 OH) (supplemental Fig. S2 
Enzymes
Escherichia coli recombinant human P450 17A1 was prepared as described (16) . E. coli recombinant rat NADPH-P450 reductase and human b 5 were prepared as described by Hanna et al. (66) and Guengerich (67) , respectively. Cholesterol oxidase (from Streptomyces sp.) was purchased from Sigma (catalogue number C8649).
Catalytic assays
Steady-state incubations-The steady-state catalytic assays were generally conducted using a reconstituted enzyme system in a final reaction volume of 0.5 ml. The reaction mixtures typically contained 0.01-0.5 M human P450 17A1, 2 M rat NADPH-P450 reductase, 0.5 M human b 5 (when included), and 16 M L-␣-1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC) (added as lipid vesicles after sonication of a 1 mg/ml aqueous stock) in 50 mM potassium phosphate buffer (pH 7.4). The P450 17A1 enzyme concentrations used were as follows: 0.01 M for incubations with pregnenolone and 17␣-OH pregnenolone; 0.01 and 0.5 M for progesterone 17␣-hydroxylation and 16␣-hydroxylation (respectively); and 0.5 M in 17␣-OH progesterone lyase assays. Substrate was added at concentrations ranging from 0.2 to 20 M. Duplicate samples were prewarmed at 37°C for 5 min (water bath with shaking), and reactions were initiated with the addition of an NADPH-generating system (10 mM glucose 6-phosphate, 0.5 mM NADP ϩ , and 2 g/ml yeast glucose-6-phosphate dehydrogenase) (68) . The mixtures were incubated for 5 min at 37°C. Reactions were quenched with 2 ml of CH 2 Cl 2 , mixed with a vortex device, and placed on ice. The samples were centrifuged to separate the organic and aqueous layers, and 1.8 ml of the organic phase was transferred to a new vessel and evaporated to dryness under a nitrogen stream. The extracts from progesterone and 17␣-OH progesterone incubations were dissolved in 100 l of a CH 3 CN/ H 2 O (1:1, v/v) mixture, and 10-l aliquots were analyzed by UPLC-UV. The pregnenolone and 17␣-OH pregnenolone incubation extracts were dissolved in 50 l of CH 3 OH, mixed with 200 l of cholesterol oxidase (0.5 units/reaction) in 50 mM potassium phosphate buffer (pH 7.4) (14, 34) , and incubated at 30°C (with shaking at 200 rpm) for 6 -12 h. The extraction procedure was then repeated, and the samples were redissolved and analyzed as progesterone, 17␣-OH progesterone, and Andro (derived from pregnenolone, 17␣-OH pregnenolone, and DHEA, respectively). The reaction products were resolved on an Acquity BEH C18 UPLC octadecylsilane column (2.1 ϫ 100 mm, 1.7 m) with mobile phases A (70% CH 3 OH, 30% H 2 O, v/v) and B (CH 3 CN), at a 0.2 ml/min flow rate. The mobile phase linear gradient proceeded as follows: 0 -1 min, 95% A; 4 min, 70% A; 4.5 min, 60% A; 4.55-6.75 min, 5% A; 7-10 min, 95% A (all v/v). The column temperature was maintained at 40°C, and the sample chamber was held at 4°C. The reaction products were identified by co-elution with commercial standards and quantified by the A 243 peak areas. The k cat and K m values were estimated using non-linear regression of hyperbolic fits in Prism software (GraphPad, San Diego).
Single-turnover conditions-Single-turnover incubations were performed using an RQF-3 quench-flow instrument (Kin-Tek Corp., Snow Shoe, PA). The instrument operates through a series of rapid mixing steps through two in-line incubation chambers, where each step dilutes the samples 2-fold. Ci/mol). The reactions were initiated by rapid mixing with 1 mM NADPH in 50 mM potassium phosphate buffer (7.4) in the first reaction chamber. The samples were incubated from 0.5 to 30 s, at which time the reactions were quenched with HCl (1 M) as they were pushed through the second reaction into the collection vessel. Four time point replicates were collected into the same vessel for analysis to compensate for the low specific activity of [ 14 C]progesterone, and the procedure was applied for the other substrates. The samples were centrifuged at 2,000 ϫ g for 5 min to eliminate precipitated protein, and the supernatant was directly injected for HPLC-UV in-line liquid scintillation counting. The reaction products were resolved on a Zorbax RX-C8 octylsilane column ( , National Diagnostics, Atlanta, GA) flow rate was 3 ml/min. The reaction products were identified by co-elution with commercial standards (monitored at A 216 (pregnenolone, 17␣-OH pregnenolone, and DHEA) and A 243 (progesterone, 17␣-OH progesterone, 16␣-OH progesterone, and Andro)) and quantified by radiochromatogram peak areas using the ␤-RAM software (Laura TM , LabLogic Systems, Brandon, FL).
Pulse-chase assays-Pulse-chase experiments were performed to follow the two-step conversion of [ 3 H]pregnenolone to [ 3 H]DHEA under steady-state and single-turnover conditions. The reconstituted enzyme/substrate mixture used in the steady-state pulse-chase assays was the same as for the protocol described for steady-state incubations, with the following alterations: (i) 0.5 M human P450 17A1, and (ii) 50 M [ 3 H]pregnenolone (13 Ci/mol). One minute after the reactions were started with the NADPH-generating system, unlabeled 17␣-OH pregnenolone was added to the mixtures, at varying concentrations (5-75 M (final concentration) and vehicle), and the incubations continued for 10 min before quenching with HCl (0.67 M final concentration). The mixtures were centrifuged to clear precipitated protein, and the steroid products were resolved and quantified by the HPLC methods employed in the single-turnover experiments (see above), with the following linear gradients: 0 -9 min, 75% B; 13.4 min, 86% B; 13.5-15 min, 90% B; 16 -25 min, 75% B (all v/v).
The pulse-chase assays done with single-turnover conditions followed a protocol similar to that outlined above, with some differences. The standard single-turnover procedure included one reaction phase, whereas a pulse-chase experiment requires two incubation periods. This was achieved in the rapid quench instrument by utilizing the second reaction chamber for incubating with a chase compound, with the quenching agent placed in the collection vial. The reagent concentrations were increased so that, after two dilutions, the working concentrations in the chase step (second phase) matched those from the single-turnover incubations. The specific activity of [ 3 H]pregnenolone was adjusted to 830 Ci/ mol, and 80 M unlabeled 17␣-OH pregnenolone was used as the chase compound. The pulse length was varied between 0.05 and 2 s, and the chase continued for 5 s before the reaction was quenched in the collection vessel with HCl (0.6 M final concentration). The mixtures were centrifuged to clear precipitated protein, and the steroid products were resolved and quantitated by the method described for the steady-state pulse-chase assays.
Orteronel inhibition-Competitive inhibition studies with the orteronel enantiomers were performed and analyzed by the methods described for steady-state assays. The inhibitors were added to the enzyme substrate mixture with the final composition as follows: 0.005-100 M (S)-or (R)-orteronel, 5 M substrate, 0.01 M human P450 17A1 (0.1 M in assays with 17␣-OH progesterone), 0.5 M human b 5 , 2 M NADPH-P450 reductase, and 16 M DLPC (lipid vesicles) in 50 mM potassium phosphate buffer (pH 7.4). To resolve an inconsistent orteronel migration profile, the mobile phase solvents were changed to 5 mM NH 4 
Binding studies
Ligand binding-Initial binding studies were performed using previously reported methods (34) . In a 10-cm cell (Starna Cells, Atascadero, CA, catalogue no. 34Q-100, 25 ml) and using an OLIS-Cary 14 spectrophotometer (On-Line Instrument Systems, Bogart, GA), the steroid ligands were incrementally added to 0.1 M human P450 17A1 in 50 mM potassium phosphate buffer (pH 7.4). Experiments were conducted as a series of additions, and the enzyme samples were exposed to ambient temperature, with mixing and exposure to a strong light beam (OLIS-Cary14 instrument) for periods Ͼ60 min. Subsequent control experiments, where ligand was not added, exhibited spectral instability in the enzyme over the same period of time. Specifically, a time-dependent decrease in the Soret band was observed, which is problematic considering that the change in the Soret band (upon ligand binding) is the outcome analyzed in the assays (no obvious precipitation occurred).
Steroid binding was reanalyzed, with fresh enzyme samples for each steroid concentration, using a stopped-flow instrument equipped with a 20-mm cell and a rapid scanning monochrometer (OLIS RSM-1000, On-Line Instrument Systems). The stopped-flow sample syringes were conditioned at 37°C and filled with either 2 M human P450 17A1 or 0.2-20 M steroid in 100 mM potassium phosphate buffer (pH 7.4) with 120 M DLPC (lipid vesicles). After mixing, the instrument recorded the absorbance spectra from 350 to 500 nm at 1-ms intervals for up to 7 s. The differential absorbance maxima and minima were determined by subtracting the final and initial (0 s) spectra. The composite absorbance changes, ⌬ (A max Ϫ A min ), from three replicates were averaged and plotted against the ligand concentrations. The data were fit with a quadratic binding formula to estimate binding constants (K d ) using GraphPad Prism, with the equation Y ϭ B ϩ (A/2)(1/E)((K d ϩ E ϩ X) Ϫ ((K d ϩ E ϩ X) 2 Ϫ (4EX))) 1/2 .
Inhibitor trapping-Spectral enzyme-inhibitor trapping assays were used to measure dissociation rates for the steroid ligands. The analysis is dependent upon a faster inhibitor binding rate versus the dissociation rates for the steroids. The experiments were performed at ambient temperature using the stopped-flow apparatus described above and (S)-orteronel as the trapping inhibitor. The on-rate for (S)-orteronel was first measured by mixing 4 M human P450 17A1 in 100 mM potassium phosphate buffer (pH 7.4) (with 120 M DLPC (lipid vesicles)) and 20 M (S)-orteronel (in the same buffer). The rate was estimated by singular value decomposition (SVD) analysis of the experimental data matrix with the following parameters: absorbance, measured value; wavelength, 350 -500 nm (200 points); and time, 0 -1 s (one scan/ms). The data were fit with a two-species sequential model (simple first-order), and the calculated rates from at least three replicates were averaged. To estimate the dissociation rates (k off ), the steroid ligands (4 M) and human b 5 (4 M, when included) were added to the enzyme solution. The time component was 0 -10 s (averaged mode, 62 scans/s), and data were analyzed as stated.
Kinetic analysis-Steroid association rate (k on ) parameters were calculated from the corresponding dissociation rates (k off ), estimated from the inhibitor trapping assays, and the dissociation constants (K d ) were derived from the steroid binding experiments, using Equation 1,
The experimental data from the catalytic assays, under single-turnover and steady-state conditions, and steroid titrations were concurrently fit to a minimal kinetic model using KinTek Explorer software (KinTek, Snow Shoe, PA). The predetermined rate parameters (k on , k off , and K d and single-turnover substrate conversion rates) were used as starting values in the model, and in some cases, the values were fixed. The limits for the molar extinction coefficients that were applied to the spectral binding experiments were derived from the prior fitting with a quadratic formula in GraphPad Prism (see above). The imported data sets included the averaged data points with standard deviation (when applicable).
To accurately fit the ligand titration and catalytic experiments in a single model, a "kinetically silent" second-order activation step was added to prevent the software from regarding the binding assay as a catalytic experiment. The activation step corresponds to the combined P450 17A1 reaction steps that lead to the chemically competent iron-oxygen species (i.e. reduction by NADPH-P450 reductase, binding of molecular oxygen, protonation, and loss of water), which were not evaluated. The concentration of the "activating reagent" was fixed at 1 M, and a K eq of 1 M was set with k forward ϭ 100 M Ϫ1 s Ϫ1 (10 8 M Ϫ1 s Ϫ1 ) and k reverse ϭ 100 s Ϫ1 , with the intention of forcing the step to be rapidly reversible to prevent any kinetic influence on the other parameters. Additionally, the reversibility accounted for uncoupling (loss of iron-oxygen species to reactive oxygen species or H 2 O, resulting in Fe 3ϩ ) that can occur during compound I (or ferric peroxide) formation. Any rate limitations derived from uncoupling were considered to be factored into the rate of the chemical reaction step. Simulations without the activation step produced similar results with the same constraints.
Steroid binding kinetics was evaluated by applying different enzyme-ligand binding models to the kinetic data obtained in stopped-flow binding assays (see under "Ligand binding") using KinTek Explorer software. The data were reduced by taking the difference of the kinetic traces (ϳ7 s trace, 1 scan/ms) at the wavelengths previously designated for A max and A min (e.g. A 391 and A 426 kinetic traces were subtracted for pregnenolone assays; see under "Ligand binding" and Figs. 5 and 12). Three replicate difference traces for each steroid concentration were averaged and then normalized to t ϭ 0. The kinetic traces were then reduced once more by boxed averaging (n ϭ 5) with standard deviation before import into the KinTek software.
